Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

NCT00759798 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

289

Enrollment

OTHER

Sponsor class

Conditions

Chronic Lymphocytic Leukemia
Leukemia

Interventions

DRUG: Fludarabine
DRUG: Cyclophosphamide
DRUG: Rituximab

Sponsor

M.D. Anderson Cancer Center